Targets › GFRA4
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2039.
Receptor for persephin (PSPN), a growth factor that exhibits neurotrophic activity on mesencephalic dopaminergic and motor neurons. Acts by binding to its coreceptor, GFRA4, leading to autophosphorylation and activation of the RET receptor. (UniProt, Q9GZZ7)
Open in Phaseline: the race on GFRA4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | CART-GFRa4 cells anti-GFRα4 CAR-T cell therapy with TCRζ/4-1BB co-stimulatory domains | GFRA4 | Phase 1 | Metastatic Medullary Thyroid Cancer | Jun 2039 |
Metastatic Medullary Thyroid Cancer (1)
mixed (1)
University of Pennsylvania (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.